News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II (World)
Wilson Therapeutics Presents Promising Neurological Phase 2 Data For WTX101 At American Academy of Neurology Meeting 4/26/2017
Galapagos (GLPG.BR) Announces New Phase II Proof-Of-Concept Study With Filgotinib In Cutaneous Lupus Erythematosus 4/26/2017
Vyome Completes Enrollment For Proof Of Concept Clinical Study Of VB 1953 In Patients With Moderate To Severe Acne 4/25/2017
ASLAN Initiates Global Pivotal Study For Varlitinib In Biliary Tract Cancer 4/25/2017
Blueberry Therapeutics Commence Phase I/II Clinical Trial Of Lead Product BB2603 4/25/2017
Finally! Novartis AG (NVS) To Release Long-Awaited Juliet CAR-T Data In June 4/25/2017
Top 15 R&D Spenders In The World For 2017 4/24/2017
Tiziana Life Sciences Plc Announces Approval Of A Phase II Clinical Trial Protocol For Milciclib In Patients With Hepatocellular Carcinoma 4/24/2017
NGM Announces NGM282 Dramatically Reduced Liver Fat And Other Biomarkers Associated With Nonalcoholic Steatohepatitis (NASH) In Phase II Trial 4/24/2017
Shionogi Presents New Clinical And Non-Clinical Data On S-033188, An Investigational Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At The 27th European Congress Of Clinical Microbiology And Infectious Diseases 4/24/2017
Mologen (MOLGF.PK): Positive Subgroup Results Of The Exploratory Phase II IMPULSE Study Of Lefitolimod In Extensive-Disease Small-Cell Lung Cancer (SCLC) 4/24/2017
Akari Therapeutics Demonstrates Positive Response With Coversin In Ongoing Phase II PNH Trial And In Additional Clinical Targets 4/24/2017
Wilson Therapeutics Presented Positive Final Phase II Data For WTX101 At EASL Annual Meeting 4/24/2017
RedHill Biopharma (RDHL) Announces Enrollment Of Last Patient In The BEKINDA Phase II Study For IBS-D 4/24/2017
Aurinia (AUPH) Releases Additional 48-Week Data From The AURA-LV Study During Late-Breaking Session At National Kidney Foundation 2017 Spring Clinical Meetings 4/21/2017
BeiGene (BGNE) Announces Initiation Of First Pivotal Study In China Of PD-1 Antibody BGB-A317 4/21/2017
Laurent Receives FDA And Health Canada Clearance To Initiate APPLAUD Phase II Clinical Study Of LAU-7b For The Treatment Of Cystic Fibrosis 4/19/2017
RedHill Biopharma (RDHL) To Host R&D Day On BEKINDA For Acute Gastroenteritis And IBS-D 4/19/2017
GeNeuro Initiates Phase IIa Study With Gnbac1 In Type 1 Diabetes In Australia 4/19/2017
Shionogi Presents New Data On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188 A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza At ECCMID 2017 4/18/2017
Circassia (CIR.L) Finally Throws In The Towel On Allergy Program After Trial Failures 4/18/2017
Protalix Biotherapeutics, Inc. (PLX) Announces Positive Results From Phase II Clinical Trial Of Alidornase Alfa (AIR Dnase) For The Treatment Of Cystic Fibrosis 4/12/2017
Argenx Launches Phase II Study Of ARGX-110 As A Monotherapy In Relapsed/Refractory CTCL Patients 4/12/2017
TRANSGENE (ENX:TNG) And Institut Bergonié Start The Phase II Part Of METROmaJX Trial 4/12/2017
3 Drug Giants That Boasts the Best Pipelines 4/11/2017
Inventiva Hits Clinical Milestone With Enrollment Of 100th Patient In IVA337 Phase IIb FASST Trial In Systemic Sclerosis (SSc) 4/10/2017
Medivir (MVRBF) Announces Positive Data From The Phase II Study Of Remetinostat In Patients With Early-Stage Cutaneous T-Cell Lymphoma 4/7/2017
Probiodrug AG Release: Last Patient Last Visit (LPLV) Reached In The SAPHIR Study 4/7/2017
Despite a Mixed PhII, Allergan (AGN) Charges Toward a Late-Stage Depression Study for Botox 4/6/2017
Oncolytics Biotech (ONC.TO)’s REOLYSIN More Than Doubles Overall Survival in Patients With Mutated p53 Metastatic Breast Cancer 4/5/2017
MediGene AG (MDGEF.PK): Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 4/5/2017
ASIT Biotech Announces That It Has Achieved The Primary Endpoint Of The Phase I/IIa Clinical Trial With Its hdm-ASIT+ Product Candidate For House Dust Mite Rhinitis 4/5/2017
Journal Of Diabetes Science And Technology Publishes Scientific Paper Authored By Oramed (ORMP) Scientists 4/4/2017
Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Completion Of Recruitment For Phase IIb Clinical Trials Of Myrcludex B In Chronic Hepatitis Delta 4/4/2017
Galapagos (GLPG.BR) Announces Three New Phase II Proof-Of-Concept Studies With Filgotinib 4/4/2017
Nanobiotix Expands Its Clinical Development In Head And Neck Cancer And I/O 4/4/2017
NovoCure Enrolls Last Patient In STELLAR Trial Testing Tumor Treating Fields In Combination With Standard Of Care Chemotherapy In Mesothelioma 3/31/2017
Akari Therapeutics Announces FDA Fast Track Designation For Coversin 3/31/2017
Opthea Conference Call/Webcast -- Update On OPT-302 Phase 1/2A Wet AMD Clinical Trial 3/31/2017
Johnson & Johnson (JNJ) Stops Mid-Stage Trial For Genmab A/S (GEN.CO)'s Blood Cancer Drug Due To Futility 3/31/2017
Takeda (TKPYY)’s Dengue Vaccine Candidate Elicited Broad Immune Responses In Children And Adolescents Living In Dengue-Endemic Areas; Interim Phase 2 Analysis Published In The Lancet Infectious Diseases 3/30/2017
Avillion Signs Clinical Co-Development Agreement With Merck & Co. (MRK) To Advance Anti IL-17 A/F Nanobody In Psoriasis 3/30/2017
Araclon Biotech Selects MedAvante Virgil Platform For Phase II Alzheimer's Trial 3/30/2017
Positive Results Of Phase IIb Clinical Trial Of Pharmalink AB's Nefecon In Primary IgA Nephropathy Published In The Lancet 3/29/2017
Clementia Release: Phase II Part A Open Label Extension Trial Of Palovarotene For Treatment Of Patients With Fibrodysplasia Ossificans Progressiva Continues Positive Trends 3/28/2017
RXi Pharma (RXII) Granted Patent In Japan For Lead Clinical Candidate RXI-109 3/28/2017
Aurinia (AUPH) Highlights 48-Week Data From Open-Label AURION Study At 12th International Congress On SLE (LUPUS 2017) & The 7th Asian Congress On Autoimmunity (ACA 2017) 3/27/2017
ERYtech Pharma Reports Positive Phase IIb Data For Eryaspase For The Treatment Of Metastatic Pancreatic Cancer 3/27/2017
Xenon Pharmaceuticals Inc. Dumps Acne Drug After Trial Failure 3/24/2017
Why Struggling Bristol-Myers Squibb (BMY) Could Take Out This Danish Biotech in Major €500M Deal 3/23/2017
Novartis AG (NVS)'s Phase III Drug for Heart Failure Bombs Trial 3/23/2017
Poxel SAS Announces Positive Results For Thorough QT Safety Clinical Study Of Imeglimin 3/21/2017
NETRIS Pharma Starts Enrollment Of First Clinical Study To Evaluate Drug Candidate Targeting Dependence Receptors 3/21/2017
NightstaRx Commences First Phase I/II Gene Therapy Clinical Trial For Patients With X-Linked Retinitis Pigmentosa 3/20/2017
BioLineRx Provides Update On Phase II Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment 3/20/2017
BioLineRx Provides Update On Phase 2 Open-Label Study For BL-8040 As Novel Stem Cell Mobilization Treatment 3/20/2017
Major Achievements In 2016 Validate TRANSGENE (ENX:TNG)’s Strategy And Provide Promising Outlook For 2017 3/20/2017
Selvita Announces First Patient Dosed In Phase I/II Clinical Trial Of SEL24 In Acute Myeloid Leukemia 3/17/2017
Karolinska Development AB Umecrine Cognition Announces First Patient Included In Clinical Phase Ib/IIa Study With GR3027 For Hepatic Encephalopathy 3/17/2017
Cytuvax Starts Its Phase II BE RESPONDER! Study Effective Vaccination For Hepatitis B Non-Responders 3/14/2017
MetrioPharm AG Announces Positive Top-Line Results From A Phase IIa Study In Moderate-To-Severe Psoriasis With Its Oral Lead Compound MP1032 3/14/2017
Sanofi (SNY) And Voluntis Announce A Global Alliance To Deliver Digital Insulin Titration Solutions For People With Type II Diabetes 3/14/2017
Kiadis Pharma To Present Atir10 Phase II Trial Data In Late Breaking Abstract At The International Society For Cellular Therapy (ISCT) 2017 Annual Meeting 3/13/2017
TiGenix Announces Top-Line Phase I/II Results Of AlloCSC-01 In Acute Myocardial Infarction 3/13/2017
Selvita To Present New Data From Its Oncology Programs At The Upcoming AACR Annual Meeting 2017 3/13/2017
First Patient Dosed In Phase 2 Trial Evaluating TRANSGENE (ENX:TNG)’s TG4010 In Combination With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 3/13/2017
Nature Cell Started Commercial Clinical Trials Phase I And II "ASTROSTEM," Stem Cell Drug For Alzheimer's Disease Treatment In U.S. 3/10/2017
REGiMMUNE Phase IIa Results Of RGI-2001, An Activator Of Invariant Natural Killer T Cells, Published In "Biology Of Blood And Marrow Transplantation" 3/10/2017
Galapagos (GLPG.BR) Release: New Phase II Studies With Filgotinib In Small Bowel And Fistulizing Crohn's Disease 3/10/2017
Bone Therapeutics Completes Recruitment Of 16 Patients In ALLOB Phase I/IIA Delayed-Union Study 3/9/2017
Menlo Therapeutics Announces Successful Pruritus Reduction Results From Phase 2 Serlopitant Trial (TCP-102) In 127 Subjects With Prurigo Nodularis 3/8/2017
Neurim Pharmaceuticals Release: Phase II Clinical Trial For Treatment Of Mild Alzheimer's Disease 3/7/2017
Aurinia (AUPH) Announces Acceptance Of Voclosporin Late-Breaking Presentation At National Kidney Foundation 2017 Spring Clinical Meetings 3/7/2017
Aurinia (AUPH) Announces Acceptance Of Voclosporin Late-Breaking Presentation At National Kidney Foundation 2017 Spring Clinical Meetings 3/7/2017
Abzena Inside Product For Neurodegenerative Conditions Moves Into Phase II Trial 3/6/2017
Kamada Ltd. (KMDA) To Host R&D Day Focused On Graft Versus Host Disease (GvHD) 3/3/2017
LEO Pharma Announces Positive Results From Phase 2b Clinical Study For Tralokinumab In Atopic Dermatitis 3/3/2017
Chugai Pharma's Anti-IL-31 Receptor A Humanized Monoclonal Antibody "Nemolizumab (CIM331)" Global Phase II Study Data Published In The New England Journal of Medicine Online 3/2/2017
SELLAS Life Sci Announces Updated Positive Phase II Data Reinforcing Meaningful Clinical Benefit Of Its WT1 Immunotherapeutic Anti-Cancer Treatment In Multiple Myeloma Patients 3/1/2017
NeuroDerm (NDRM) Achieves Primary Endpoint In ND0612H Phase II Trial For Advanced Parkinson’s Disease; Seeks Broader EU Label Based On Indigo Trial Following EMA Meeting 3/1/2017
Roche (RHHBY)'s Renal Success Spells Danger For All-Comer Studies 2/27/2017
Addex Therapeutics (ADXN.SW)'s ADX71149 Anti-Epileptic Effect Highlighted In Scientific Journal, Epilepsia 2/27/2017
Resverlogix (RVX.TO) Reports Positive FDA Type B Meeting On Design Issues Relating To A Proposed Phase IIa Kidney Dialysis Trial 2/23/2017
Minoryx Therapeutics Receives Orphan Drug Designation From The FDA For Its Lead Candidate MIN-102 2/22/2017
Immuron Completes Phase II NASH Clinical Trial Recruitment 2/21/2017
Cell Medica: Lead Cancer Immunotherapy Candidate Receives FDA Fast Track Designation 2/21/2017
OncoGenex (OGXI) Announces Phase II Apatorsen Data For Two Clinical Trials Presented At The OncoGenex (OGXI) 2017 Genitourinary Cancers Symposium 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
Apitope Announces Positive ATX-MS-1467 Phase IIa Data In Relapsing Multiple Sclerosis 2/21/2017
Hutchison China MediTech (Chi-Med) Initiates A Phase II Study Of Savolitinib In Pulmonary Sarcomatoid Carcinoma 2/20/2017
Could Marijuana Be the Next Miracle Drug For Treating Cancer? 2/20/2017
ASLAN Receives Orphan Drug Designation In Korea For Varlitinib (ASLAN001) In Biliary Tract Cancer 2/20/2017
Ascendis Announces Publication Of Comprehensive Results From Randomized, Active-Controlled Phase 2 Trial Of Once-Weekly Transcon Growth Hormone In Pediatric Patients 2/17/2017
Hutchison China MediTech (Chi-Med): Savolitinib PRCC Results Presentation At ASCO GU 2/14/2017
Allergan (AGN) R&D Chief Reveals 6 Drugs That Could be Potential Blockbusters 2/14/2017
Biotron Limited (BIT:AU) Release: Commencement Of BIT225 Phase ll HIV-1 Clinical Trial 2/13/2017
MMJ PhytoTech Phase ll Clinical Trial For Treatment of Epilepsy Underway 2/13/2017
Boehringer Ingelheim Release: Afatinib To Be Evaluated In Combination With PD-1 Inhibitor Pembrolizumab In New Trial For Patients With Squamous Cell Carcinoma Of The Lung 2/9/2017
CRT Pioneer Fund And Cardiff University Announce The Initiation Of The Phase II MONOCLE Study Of Tefinostat For The Treatment Of Chronic Myelomonocytic Leukaemia With Funding To Progress Further Development 2/8/2017
GlaxoSmithKline (GSK)'s Incoming CEO Preps for Deals, R&D Decisions on New Drugs 2/7/2017
Immuron Announces First Patient Enrolled In Pediatric Fatty-Liver Phase II Trial 2/7/2017
Another Letdown for Bristol-Myers Squibb (BMY) as Partner Innate Pharma (IPH.PA )'s Leukemia Candidate Flunks Phase II Test 2/6/2017
Zealand Pharma  (ZEAL.CO) Release: Patient Recruitment Completed For Phase II Trial With Glepaglutide For Treatment Of Short Bowel Syndrome 2/6/2017
DBV Tech Announces Completion Of Enrollment Of Phase IIA Study Of Viaskin Milk For The Treatment Of Pediatric Eosinophilic Esophagitis 2/3/2017
Galapagos (GLPG.BR) Doses First Patient With Novel CF Corrector GLPG2222 2/2/2017
Medivir (MVRBF) Release: MIV-711 Osteoarthritis Trial: Successful Fourth Independent Review Of Safety Data Enables Trial Continuation Without Any Modifications 2/1/2017
TiGenix Enrolls First Patient iIn Phase Ib/IIa Clinical Trial Of Cx611 In Severe Sepsis 1/31/2017
Scientists Highlight the Hopes and Fears of Cellectis (ALCLS)' CAR-T 1/26/2017
Biomay AG Release: Company Reports Positive Results From A Second Phase Ilb Trial With The Innovative 3rd Generation Grass Pollen Allergy Vaccine Bm32 1/26/2017
4SC (VSC.F) Release: Overall Survival Benefit For Resminostat In First-Line Liver Cancer Study Subgroup 1/26/2017
Novartis AG (NVS) Shows Off 13 Potential Blockbusters in Pipeline 1/25/2017
DelMar Pharma Release: Company And MD Anderson Cancer Center Initiate New Phase Two Clinical Trial Of VAL-083 For MGMT-Unmethylated Recurrent Glioblastoma Multiforme (GBM) 1/25/2017
ProMetic Life Sci (PFSCF.PK) Release: Company's PBI-4050 Receives Promising Innovative Medicine Designation From The UK MHRA For The Treatment Of Alström Syndrome 1/24/2017
Genmab A/S (GEN.CO) Release: Company Provides Clinical And Regulatory Update For NCX 470 For IOP Lowering 1/24/2017
Kamada Ltd. (KMDA) Release: Company Announces Positive Scientific Advice Response From The EMA Focused On Alpha-1 Antitrypsin IV For Treatment Of Acute Graft-Versus-Host Disease 1/23/2017
Sanifit Release: Biopharma Announces Enrollment Of First Patient In CaLIPSO – A Phase Ilb Study For The Treatment Of Cardiovascular Calcification In End-Stage-Renal-Disease Patients On Haemodialsis 1/23/2017
Prima Biomed (PRR.AX) Release: Company Commences Randomised Phase IIb Clinical Trial For IMP321 In Breast Cancer 1/20/2017
ProMetic Life Sci (PFSCF.PK) Releaase: European Commission (EC) Grants Orphan Drug Designation To Company's PBI-4050 Drug For The Treatment Of Alström Syndrome 1/18/2017
Daiichi Sankyo Release: Company Initiates Phase 1/2 Study Of Novel Antibody Drug Conjugate U3-1402 In Patients With HER3-Positive Metastatic Or Unresectable Breast Cancer 1/18/2017
BioLineRx Release: Pharma Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA For Pancreatic Cancer 1/17/2017
AiCuris Release: Pharma Announces Publication Of Phase 2 Clinical Trial Results Of Investigational Anti-Herpes Simplex Virus Agent Pritelivir In JAMA 1/17/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Study Of Sulfatinib In Second-Line Biliary Tract Cancer In China 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Biopharma Initiates A Phase II Combination Study Of Fruquintinib With Iressa (Gefitinib) In First-Line Non-Small Cell Lung Cancer 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Sulfatinib Phase II Study In 2nd Line BTC In China 1/16/2017
Hutchison China MediTech (Chi-Med) Release: Fruquintinib Combination Study In 1st-Line NSCLC 1/16/2017
Shionogi Release: Pharma Announces Positive Top-Line Results For Cefiderocol Pivotal cUTI Clinical Trial 1/12/2017
MorphoSys AG Release: Company Partner To Start Phase 2 Trial With Bimagrumab In Obese Patients With Type 2 Diabetes 1/12/2017
JPM17: CureVac Release: Biotech's mRNA Program Fails Phase II Test, Putting Spotlight on Other Biotechs Like Moderna 1/12/2017
Affimed (AFMD) Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform 1/11/2017
Sobi Release: First Patient Randomized In A Phase II Study Evaluating The Safety And Efficacy Of Anakinra In The Treatment Of Acute Gout 1/11/2017
Debiopharm Release: Biopharma Announces Positive Phase 2 Clinical Trial With Debio 1450 In ABSSSI Patients 1/10/2017
ThromboGenics NV (TBGNF) Release: Pharma Enrolls First Patients In Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) For Diabetic Macular Edema (DME) 1/10/2017
Finding a Complementary Secondary Endpoint in Lupus Clinical Trials 1/10/2017
Galmed Pharmaceuticals Completes Patient Recruitment For ARREST Phase IIb NASH Study 1/9/2017
Can-Fite BioPharma (CFBI) Receives IRB Approval To Commence Patient Enrollment In Phase II NAFLD/NASH Trial In Q1 2017 1/9/2017
Probiodrug AG Announces Completion Of Recruitment For The SAPHIR Phase 2a Study Of Glutaminyl Cyclase Inhibitor PQ912 In Early Alzheimer's Disease Patients 1/9/2017
TLC Biopharmaceuticals, Inc. Reports Results Of Phase 1/2 Clinical Trial Of TLC599 For Sustained Pain Relief In The Treatment Of Osteoarthritis Of The Knee 1/6/2017
US FDA Grants Orphan Drug Designation To YiSheng BioPharma's PIKA Rabies Vaccine 1/4/2017
Senhwa Biosciences CX-4945 Granted Orphan Drug Designation By The US FDA In Cholangiocarcinoma 1/4/2017
Ogeda Announces Positive Data From Phase IIa Trial Of Fezolinetant (ESN364) In The Treatment Of Menopausal Hot Flashes 1/4/2017
Inventiva Announces Initiation Of Phase IIb Clinical Trial Of IVA337 For Treatment Of Non-Alcoholic Steatohepatitis (NASH) 1/3/2017
Bavarian Nordic (BAVA.CO) Initiates Trial Of CV301 In Combination With Nivolumab In Patients With Lung Cancer 12/29/2016
ThromboGenics NV (TBGNF) Announces Protocol Amendment To Phase II CIRCLE Trial Evaluating THR-409 (Ocriplasmin) In Patients With Non-Proliferative Diabetic Retinopathy (NPDR) 12/28/2016
Unexpected Clinical Results Cause Hansa Medical to Terminate Phase II With IdeS in Acquired TTP 12/21/2016
After Terminating BI-505 Phase II, BioInvent (BOVNF) Rebounds With Big Pharma Deal 12/21/2016
Genmab A/S (GEN.CO) Announces Submission Of Regulatory Application For Daratumumab In Relapsed/Refractory Multiple Myeloma In Japan And Updates Financial Guidance 12/20/2016
GenSight Biologics Reports Sustained Visual Acuity Gain At 78 Weeks In Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 12/20/2016
Prima Biomed (PRR.AX) Receives UK Approval For AIPAC Study 12/20/2016
Astellas (ALPMY) Announces FDA Fast Track Designation For ASP0892, DNA Vaccine For Mitigation Of Severe Hypersensitivity Reactions Due To Peanut Allergy 12/20/2016
Genticel Reports Final Results Of GTL001 Phase II Trial In HPV16/18-Infected Women 12/14/2016
Zealand Pharma  (ZEAL.CO) Initiates Phase IIa Clinical Trial With Dasiglucagon In A Dual-Hormone Artificial Pancreas System From Beta Bionics 12/13/2016
MorphoSys AG Starts Phase 2 Trial Of MOR208 In Combination With Idelalisib In Patients With Relapsed Or Refractory CLL Or SLL Previously Treated With A BTK Inhibitor 12/13/2016
PHARNEXT Presents Positive Exploratory Phase 2 Data From PXT864 At The 9th Clinical Trials On Alzheimer’s Disease (CTAD) Conference In San Diego, United States 12/13/2016
NovoCure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel May Be Safe As First-Line Treatment And May Improve Survival Of Patients With Recurrent Ovarian Cancer 12/13/2016
NovoCure Presents Second Cohort Of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel And Gemcitabine May Be Safe As First-Line Treatment And May Improve One-Year Survival Rate Of Patients With Advanced Pancreatic Cancer 12/13/2016
Axovant (AXON) Unveils New Data Analysis Showing Addition Of Intepirdine To Standard Therapy May Help People With Alzheimer's Disease Maintain Independence Longer 12/12/2016
RedHill Biopharma (RDHL) Announces Phase IIa 48-Week Final Results Further Supporting Potential Of RHB-104 In Multiple Sclerosis 12/12/2016
BioInvent (BOVNF) Terminates Current BI-505 Phase II Study 12/9/2016
Probiodrug AG Release: Innovative Phase II Study Design Of Glutaminylcyclase Inhibitor PQ91 In Early Alzheimer’s Disease 12/8/2016
Neovacs Obtains FDA “Fast Track” Designation For IFNa Kinoid In Lupus (SLE) 12/7/2016
TRANSGENE (ENX:TNG), UC Davis To Conduct Phase II Trial Of The Combination Of TG4010 With Opdivo (Nivolumab) For 2nd Line Treatment Of Metastatic Non-Small Cell Lung Cancer (NSCLC) 12/7/2016
Kiadis Pharma Presents Positive 1-Year Follow-Up Data Of Its Pivotal Phase II Trial With ATIR101 12/6/2016
Gamida Cell Presents Positive Data From Phase 1/2 Study Of NiCord as A Curative Treatment For Sickle Cell Disease At American Society of Hematology 2016 12/6/2016
Novartis AG (NVS)’ CAR-T Drug Sends 82% of Patients’ Blood Cancer into Remission, Eyes 2017 for Marketing 12/6/2016
ReNeuron Release: Reports Positive Results In Phase II Stroke Trial 12/5/2016
BioLineRx Presents Positive Phase 2a AML Study And Mechanism-Of-Action Data For BL-8040 Oncology Platform At American Society of Hematology 2016 12/5/2016
Poxel SAS Release: Ability To Delay Type 2 Diabetes Disease Progression By Preserving Beta Cell Mass Observed In New Imeglimin Data 12/5/2016
BiondVax Pharmaceuticals Phase 2b Trial Preliminary Safety Results: The Universal Flu Vaccine Candidate Is Safe And Well Tolerated 11/29/2016
BerGenBio AS Reports Promising BGB324 Phase I/II Monotherapy Data In Patients With Lung Cancer At The EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 11/29/2016
Araim Pharmaeuticals Release: ARA 290 Obtains European Union Orphan Drug Designation For Prevention Of Graft Loss In Pancreatic Islet Transplantation 11/28/2016
Nanobiotix Provides Update On Global Development Of Lead Product NBTXR3 11/28/2016
Medivir (MVRBF) Announces That Janssen Has Initiated An Open-Label Phase IIb Study Of The 3DAA Combination Of Simeprevir, Odalasvir And AL-335 (JNJ-4178) 11/28/2016
Nature Cell Receives U.S. FDA Approval For Phase I And II Alzheimer's Clinical Trial 11/28/2016
Opthea Completes Patient Enrolment In Phase 1/2A Wet AMD Clinical Trial 11/22/2016
Ability Pharma Initiates Phase 2 Combination Trial With ABTL0812 As First Line Therapy In Patients With Endometrial Or Squamous Lung Cancer Patients 11/22/2016
Mallinckrodt (MNK) Will Initiate Company-Sponsored Clinical Trial Of H.P. Acthar Gel In Treatment Of Amyotropic Lateral Sclerosis (ALS) 11/21/2016
ProMetic Life Sci (PFSCF.PK) Receives Clearance From Health Canada To Proceed With Its PBI-4050 Placebo-Controlled Phase 2 Clinical Trial In Patients With Metabolic Syndrome And Type 2 Diabetes 11/16/2016
Genexine Co. Ltd. Granted FDA Orphan Drug Designation For GX-H9 In Growth Hormone Deficiency 11/16/2016
Tiziana Life Sciences Plc Announces New Data With Foralumab, A Fully Human Anti-CD3 Antibody Being Developed As An Oral Therapy For NASH And Autoimmune Diseases 11/16/2016
Merck KGaA (MKGAF.PK)'s Atacicept Flops in Phase IIb Lupus Study But Firm Remains Upbeat 11/15/2016
Karolinska Development AB Company Modus Therapeutics’ Ongoing Clinical Study With Sevuparin In Sickle Cell Disease Expands To Include Adolescent Patients 11/15/2016
Zytoprotec GmbH Phase II Peritoneal Dialysis Study: Last Patient Out 11/14/2016
AstraZeneca PLC (AZN) Faces Another R&D Setback as Plans to File for Early Approval for Cancer Med are Scrapped 11/10/2016
Cerenis Therapeutics, Inc. Announces Last Patient Dosed In CARAT Phase II Study With CER-001 In Post-Acute Coronary Syndrome Patients 11/8/2016
Ascend Biopharmaceuticals Announces Encouraging Phase I/IIa Interim Results Of ASN-002 Treatment Of Nodular Basal Cell Carcinoma (nBCC) 11/8/2016
FDA Slaps a Full Clinical Hold on BioInvent (BOVNF)'s Phase II Multiple Myeloma Study 11/8/2016
Neovacs Enrolls The First U.S. Patient In Phase IIb Study Of Ifna Kinoid For Treatment Of Systemic Lupus Erythematosus (SLE) 11/7/2016
Sanofi (SNY) and Novartis AG (NVS) are the Worst Culprits in Reporting Clinical Trial Data, Shire (SHPG) the Best 11/4/2016
GENFIT (ALGFT): FDA Has Officially Cleared The IND To Proceed With Phase II Trial And Evaluate Elafibranor In PBC 11/4/2016
Safety Review Committee For Nordic Nanovector's Lymrit 37-01 Trial Recommends Dose Escalation To 20 MBq/kg With Betalutin 11/4/2016
Four Patients Suffered Serious Adverse Events While on Roche (RHHBY)'s Breakthrough Hemophilia Drug 11/3/2016
One Out of the Two Reasons Allergan (AGN) Paid $640 Million for Vitae Pharma (VTAE) Just Flunked Mid-Stage Test 11/3/2016
Sanofi Genzyme (SNY) Release: Pivotal Phase 2/3 Trial Of Olipudase Alfa For Adult Patients With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B) To Begin In The UK 11/3/2016
BioLineRx Discloses Positive Correlative Data From Phase 2a AML Study And Mechanism-Of-Action Data For BL-8040 Oncology Platform At American Society of Hematology 2016 11/3/2016
Towards The Company's First Clinical Trial; Kadimastem Signs Letter Of Intent With Hadassah Medical Center For Performance Of The Clinical Trial In ALS 11/3/2016
Nordic Nanovector: Updated Results From Phase 1/2 Trial Of Betalutin In Non-Hodgkin Lymphoma To Be Presented At American Society of Hematology Annual Meeting In December 11/3/2016
Helsinn And MEI Pharma (MEIP) Announce Long-Term Survival And Response Data From Phase II Clinical Study Of Pracinostat In Acute Myeloid Leukemia Accepted For Oral Presentation At Upcoming American Society of Hematology Annual Meeting 11/3/2016
Kamada Ltd. (KMDA) Announces Plan For Phase II/III Clinical Trial With Alpha-1 Antitrypsin IV For Treatment Of Graft-Versus-Host Disease 11/2/2016
Merck KGaA (MKGAF.PK), Darmstadt, Germany, Presents Phase II Data On The Safety And Efficacy Of Atacicept At The 2016 ACR/ARHP Annual Meeting 11/2/2016
Medivir (MVRBF): MIV-711 Osteoarthritis Program: Enrollment In The Phase IIa Study Is Complete And Independent Safety Review Committee Again Recommends Go Ahead 10/27/2016



//-->